Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ayahuasca/Schizophrenia

Ayahuasca for Schizophrenia

10 papers and 0 clinical trials exploring ayahuasca as a treatment for schizophrenia.

Compoundclassic psychedelic

Ayahuasca

Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.

Full Ayahuasca profile
IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

10 papers
Open Accessmeta

‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression

In a pre-registered meta-analysis of 8 PAT trials (548 patients) and 16 open‑label traditional antidepressant studies (9,751 patients), psychedelic-assisted therapy was not more effective than open‑label antidepressants on the 17‑item Hamilton Depression Rating Scale (difference 0.3 favouring tAD; 95% CI −1.39 to 1.98; p=0.73). This equal‑unblinding comparison emphasises that blinding integrity materially influences apparent treatment effects and that both PAT and tAD produced robust, clinically meaningful improvements.

Published
June 9, 2025
Journal
OSF Preprints
Authors
Williams, Z. J., Barnett, H., Szigeti, B.
Open Accessindividual

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

This retrospective case study describes a woman with bipolar disorder and psychotic features whose suicidality, dissociation and social isolation markedly improved and were sustained after multiple ayahuasca ceremonies, with corroboration of childhood abuse and ongoing symptom reduction over several years. The report suggests potential therapeutic benefits of ayahuasca for severe traumatisation and bipolar symptoms and situates the case within a brief review of low‑dose ayahuasca and LSD treatment literature.

Published
March 10, 2023
Journal
Psyarxiv
Authors
Turkia, M.
Open Accessmeta

Default Mode Network Modulation by Psychedelics: A Systematic Review

This systematic review shows that classical psychedelics (LSD, psilocybin, ayahuasca) consistently cause acute disruption of resting-state connectivity within the Default Mode Network and increase cross-network functional connectivity, but it remains unclear how central DMN modulation is to their therapeutic effects. The article synthesises existing evidence and highlights gaps to guide future mechanistic research.

Published
October 22, 2022
Journal
International Journal of Neuropsychopharmacology
Authors
Gattuso, J. J., Perkins, D., Ruffell, S. G. D., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D. J., Sarris, J.
Paywallmeta

The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies

This meta-analysis (2021) of brain imaging studies finds that under the influence of psychedelics (tryptamines), the most changes in connectivity are indeed the ones where there are the most 5-HT1a/2a receptors. Other regions are also highlighted, and these regions most influenced are responsible for mental imagery, theory of mind, and affective regulation.

Published
September 7, 2021
Journal
Frontiers in Pharmacology
Authors
Castelhano, J. M., Lima, G. M., Teixeira, M., Soares, C., Pais, M., Castelo-Branco, M.
Paywallmeta

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

This systematic review (2020) looked at 10 modern studies (n=188) on psychedelics (psilocybin, ayahuasca, LSD) for the treatment of a variety of mental health disorders. The review found the studies to provide evidence for efficacy (up to months later) and safety.

Published
October 30, 2020
Journal
Acta Psychiatrica Scandinavica
Authors
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J., Erritzoe, D.
Open Accessmeta

Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

This systematic review of case reports found that psychotic episodes following ayahuasca or DMT use are rare but have been documented in both ritual and recreational/non‑controlled settings. Most reported cases involved a personal or family history of psychosis, bipolar/manic disorders or concomitant substance use, supporting psychiatric screening before administration and avoidance of hallucinogens in those with such histories.

Published
February 23, 2017
Journal
Therapeutic Advances in Psychopharmacology
Authors
Dos Santos, R. G., Hallak, J. E., Bouso, J. C.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ayahuasca and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ayahuasca papers Search all Schizophrenia trials Full Ayahuasca profile Full Schizophrenia profile